Alicia Bigica

The drug, marketed as Beyfortus, was approved by the FDA in July for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Research findings may support further COVID-19 vaccination in children.

A study presented at IDWeek 2023 showed significantly more patients in the treatment group were alive and oxygen-free by day 29 and day 60 compared to those in the placebo group.

Based on data from an ongoing clinical trial and other studies, the R21 vaccine has been shown to have a high degree of efficacy when administered just before the high transmission season, with data showing a 75% reduction in cases of malaria in the 12 months following the 3-dose series.

Beyond female gender, comorbidities independently associated with C diff infection in patients diagnosed with COVID-19 included peptic ulcer disease, renal failure, weight loss, diabetes mellitus with complications, and congestive heart failure.